An interventional study of Transcranial ultrasound stimulation in Cognitive Deficit in Schizophrenia, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Schizophrenia by Shanghai Mental Health Center — 15 open to participants now, 15 under way, none of them phase 3. Schizophrenia · Shanghai Mental Health Center.
Among the 61 studies in Schizophrenia by Shanghai Mental Health Center, this one is the 14th largest by planned enrollment of the 50 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 53rd registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →15 of the 61 studies in Schizophrenia by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–45
Shanghai Mental Health Center · Sites in China
Ages 18–45
Shanghai Mental Health Center · Sites in China
Ages 13–55
Shanghai Mental Health Center · Sites in China
Ages 18+
Shanghai Mental Health Center · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 4 · Phase 4 8
First in 2008; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 67 across the 50 interventional studies, 480 across the 11 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 95 are open to participants now.
5 of the studies in Schizophrenia by Shanghai Mental Health Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT06802939Shanghai Mental Health CenterRTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography | 2026-12-10 |
| NCT07767526Shanghai Mental Health CenterXingqi Daozhi Decoction for Antipsychotic-Induced Constipation | 2027-06-01 |
| NCT06904092Shanghai Mental Health CenterEfficacy and Mechanisms of TUS on Cognitive Deficits in Schizophrenia: Based on the Hippocampal-Prefrontal Circuit | 2027-10-31 |
| NCT05159349Shanghai Mental Health CenterMental Health During the Whole Life Cycle of Community Patients With Schizophrenia | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Schizophrenia by Shanghai Mental Health Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cognitive deficit is a core symptom of schizophrenia related to poorer functional outcome. Prior studies indicated that abnormalities in the hippocampus-prefrontal circuit and glutamate/GABA imbalances may lead to cognitive deficits. Based on the current background and our previous studies, it has been proved that TUS can modulate neural excitability and plasticity in the hippocampus. In this double-blind, randomized study, the efficacy of different treatment options and mechanisms of TUS on cognitive deficits will be investigated.
Cognitive deficit is a core symptom of schizophrenia related to poorer functional outcome which remains largely treatment refractory. Prior studies indicated that abnormalities in the hippocampus-prefrontal circuit and glutamate/GABA imbalances may be the root causes of cognitive deficits. Transcranial ultrasound stimulation (TUS), an emerging non-invasive neuromodulation technique with deep penetration ability, can modulate neural excitability and plasticity in the hippocampus. This is a 4-week double-blind randomized trial of TUS for cognitive deficits in schizophrenia, with either left hippocampus or left dorsolateral prefrontal cortex (DLPFC) or both targeted. This study aims to determine the efficacy of TUS and to reveal its underlying neural mechanism, especially with the hippocampus-prefrontal circuit, by means of TUS, as to assess cortical inhibition and excitability, EEG source imaging, and multi-model MRI. Neuropsychological assessments will also be conducted to develop the optimized treatment strategy. The study points to a novel and promising therapeutic neuromodulation approach that may improve the functional outcome of schizophrenia, which has been the main cause of mental disability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
35 eligible patients will be treated with active TUS on the left DLPFC and sham TUS on the left hippocampus for 4 weeks
Device: Transcranial ultrasound stimulation
35 eligible patients will be treated with active TUS on the left hippocampus and sham TUS on the left DLPFC for 4 weeks
Device: Transcranial ultrasound stimulation
35 eligible patients will be treated with active TUS for 4 weeks on the left DLPFC and left hippocampus
Device: Transcranial ultrasound stimulation
35 eligible patients will be treated with sham TUS for 4 weeks on the left DLPFC and left hippocampus
Device: Transcranial ultrasound stimulation
The TUS was administered using Transcranial Ultrasound Stimulator UNS-III (model UNS-III), which has passed the safety test for medical electrical equipment (GB9706.1-2007). Transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
Change from baseline in associative memory test score
Change from baseline in the associative memory test score at 4 weeks and 8 weeks.
Time frame: baseline, 4 weeks and 8 weeks
Change of information processing speed and attention/vigilance
Change from baseline in 4 MCCB subtests score at 4 weeks and 8 weeks.
Time frame: baseline, 4 weeks and 8 weeks
Change of working memory
Change from baseline in N-back task at 4 weeks and 8 weeks. The outcome measures include accuracy, D-prime value, and reaction time.
Time frame: baseline, 4 weeks and 8 weeks
Change from baseline in Positive and Negative Syndrome Scale(PANSS)
Change from baseline in Positive and Negative Syndrome Scale(PANSS) at 4 weeks and 8 weeks. The minimum to maximum value is 30-210. Lower scores mean a better outcome.
Time frame: baseline, 4 weeks and 8 weeks
Change of CGI score
Change from baseline in Clinical Global Impression (CGI) at 4 weeks and 8 weeks.
Time frame: baseline, 4 weeks and 8 weeks
Change of Multi-modal Brain Neuroimaging in structure
Brain structure data will be acquired.
Time frame: baseline and 4 weeks
Change of Multi-modal Brain Neuroimaging in resting- state fMRI
Resting-state fMRI data will be acquired.
Time frame: baseline and 4 weeks
Change of Multi-modal Brain Neuroimaging in 1H-MRS
1H-MRS data will be acquired.
Time frame: baseline and 4 weeks
Change of 64 channels EEG
64 channels EEG data will be acquired.
Time frame: baseline and 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Oct 2027, 15 months later.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 15 months is below that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Mental Health Center →